Tech Company Financing Transactions
Pliant Therapeutics Funding Round
Third Rock Ventures and private investors participated in a $45 million Series A funding round for Pliant Therapeutics. The financing round was recorded on 2/19/2016.
Transaction Overview
Company Name
Announced On
2/19/2016
Transaction Type
Venture Equity
Amount
$45,000,000
Round
Series A
Investors
Third Rock Ventures (Neil Exter)
Proceeds Purpose
Pliant's product engine has the potential to address the needs of many patients by targeting fibrosis in a variety of organs and conditions, including the lungs (IPF), liver (NASH and cirrhosis), kidney (renal fibrosis), skin (scleroderma), heart (cardiac fibrosis) and the gastrointestinal tract (Crohn's disease).
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
260 Littlefield Ave.
San Francisco, CA 94080
USA
San Francisco, CA 94080
USA
Phone
Website
Email Address
Overview
Pliant Therapeutics (Nasdaq: PLRX) is focused on discovering, developing and commercializing breakthrough treatments for fibrotic diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Bernard Coulie
Chief Financial Officer
Keith Cummings
Chief Medical Officer
Eric Lefebvre
Vice President
Katerina Leftheris
Vice President
Scott Turner
VP - Bus. Development
Hans Hull
VP - Bus. Development
Eve-Irene Lepist
VP - Human Resources
Barbara Howes
VP - Operations
Marzena Jurek
Browse more venture capital transactions:
Prev: 2/19/2016: Armune BioScience venture capital transaction
Next: 2/19/2016: eFFECTOR Therapeutics venture capital transaction
Share this article
About Database of VC Transactions
Our team works diligently to report on funding rounds that are announced publicly. VC transactions reported here are sourced from company press releases and news coverage. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs